SC
CLRB icon

Sophrosyne Capital’s Cellectar Biosciences CLRB Stock Holding History

Sophrosyne Capital’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5
Closed -$441K – 36
2014
Q4 		$441K Sell
5
-1
-17% -$77K 0.68% 27
2014
Q3 		$389K Buy
+6
New +$518K 0.46% 39

Other funds holding CLRB

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SSB
Sandy Spring Bank Olney, Maryland $2.38B AUM 8.14% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Sophrosyne Capital's CLRB Position: Q1 2015 in Review

Sophrosyne Capital sold out of Cellectar Biosciences (CLRB) in Q1 2015, closing a stake of 5 shares — an estimated $441K sold.

Sophrosyne Capital first reported a position in CLRB in Q3 2014 and held it in 2 quarters. The position peaked at $441K in Q4 2014. 5 funds tracked by Wall St. Rank hold CLRB as of Q1 2015.

  • Sophrosyne Capital reported no remaining Cellectar Biosciences position as of Q1 2015 after selling out during the quarter.
  • Sophrosyne Capital sold 5 Cellectar Biosciences shares in Q1 2015, an estimated $441K.
  • Sophrosyne Capital first reported a position in Cellectar Biosciences in Q3 2014 and held it in 2 quarters.
  • Sophrosyne Capital's Cellectar Biosciences position peaked at $441K in Q4 2014.
  • 5 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2015.

Based on Sophrosyne Capital's 13F filing for Q1 2015, filed 20 Apr 2015.